Innovent Reports Positive Data from Phase III Trial of Tyvyt for NSCLC

Suzhou Innovent Biologics reported positive interim data from a China Phase III trial of Tyvyt®, the company's PD-1 treatment, as a first-line treatment for patients with non small cell lung cancer (NSCLC). Tyvyt®, in combination with Alimta® (pemetrexed) and platinum chemotherapy, increased median progression-free survival to 8.9 months compared to 5.0 months for the two drugs without Tyvyt. In April, Innovent and Eli Lilly, its Tyvyt partner, filed for China approval of the combination therapy in NSCLC. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //